Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL331 Target Snapshot

Cyclin-dependent kinase 4 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,436Compounds
358Assays
12Approved Drugs
2,277.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Cyclin-dependent kinase 4 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P11802. Start with breast cancer, then reuse UniProt P11802 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with breast cancer, then reuse UniProt P11802 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 6 linked drugs
Open source guide
Disease program
breast cancer

Cyclin-dependent kinase 4 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 6 linked drugs remain visible in the same block.

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include ABEMACICLIB, ALVOCIDIB, RIBOCICLIB, RIBOCICLIB SUCCINATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 6 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cyclin-dependent kinase 4 as ChEMBL target CHEMBL331, mapped to UniProt P11802. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cyclin-dependent kinase 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL331
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P11802
Cyclin-dependent kinase 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cyclin-dependent kinase 4 is the right protein anchor across sources, using UniProt P11802 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why breast cancer is currently framed as approved-linked support. It currently carries 6 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameCyclin-dependent kinase 4
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP11802
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCyclin-dependent kinase 4
UniProt AccessionP11802
Component TypeProtein
Sequence Length303 aa

Cyclin-dependent kinase 4

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Cyclin-dependent kinase 4, mapped to UniProt P11802. Sequence length is 303 aa.

Mapped IDP11802
Review nameCyclin-dependent kinase 4
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Cyclin-dependent kinase 4 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
breast cancer
6 linked drugs · 6 direct · 6 efficacy
Linked drugABEMACICLIB
Linked drugALVOCIDIB
Linked drugRIBOCICLIB
Linked drugRIBOCICLIB SUCCINATE
Approved-linked Approved
neoplasm
6 linked drugs · 6 direct · 6 efficacy
Linked drugABEMACICLIB
Linked drugALVOCIDIB
Linked drugRG-547
Linked drugRIBOCICLIB
Approved-linked Approved
breast neoplasm
4 linked drugs · 4 direct · 4 efficacy
Linked drugABEMACICLIB
Linked drugRIBOCICLIB
Linked drugRIBOCICLIB SUCCINATE
Linked drugTRILACICLIB
Approved-linked Approved
breast carcinoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugABEMACICLIB
Linked drugRIBOCICLIB
Linked drugRIBOCICLIB SUCCINATE
Approved-linked Approved
cancer
3 linked drugs · 3 direct · 3 efficacy
Linked drugABEMACICLIB
Linked drugRIBOCICLIB
Linked drugVORUCICLIB
Approved-linked Approved
small cell lung carcinoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugTRILACICLIB
Linked drugTRILACICLIB DIHYDROCHLORIDE
Linked drugUCN-01
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include ABEMACICLIB, ALVOCIDIB, RIBOCICLIB, RIBOCICLIB SUCCINATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebreast cancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

12
Approved
9
Phase III
19
Phase II
9
Phase I
Assay Mix

Activity Type Distribution

IC501,771.0
KI117.0
KD389.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL151546 10.59 IC50 0.026 Preclinical
CHEMBL5841163 10.15 IC50 0.07 Preclinical
CHEMBL148580 10.1 IC50 0.08 Preclinical
CHEMBL6064669 10.1 IC50 0.08 Preclinical
CHEMBL5765852 10.0 IC50 0.1 Preclinical
CHEMBL5941236 9.96 IC50 0.11 Preclinical
CHEMBL6043427 9.96 IC50 0.11 Preclinical
CHEMBL5748748 9.92 IC50 0.12 Preclinical
CHEMBL3698644 9.89 IC50 0.13 Preclinical
CHEMBL4446357 9.89 Ki 0.13 Clinical
Distribution

pChEMBL Value Distribution

60
5.0
103
5.5
126
6.0
150
6.5
206
7.0
265
7.5
321
8.0
351
8.5
64
9.0
19
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
Properties Compare Identifier
ENCORAFENIB
CHEMBL3301612
Approved 2018
Properties Compare Identifier
ABEMACICLIB
CHEMBL3301610
Approved 2017
Properties Compare Identifier
RIBOCICLIB
CHEMBL3545110
Approved 2017
Properties Compare Identifier
PALBOCICLIB
CHEMBL189963
Approved 2015
Properties Compare Identifier
NINTEDANIB
CHEMBL502835
Approved 2014
Properties Compare Identifier
DABRAFENIB
CHEMBL2028663
Approved 2013
Properties Compare Identifier
Assay Landscape

Assay Landscape

359
Total Assays
1,428
Tested Compounds
3
Assay Types
Binding — 306 assays, 1,428 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 232 1,386 7.6
cell-based format 47 25 6.4
subcellular format 14 13 6.3
assay format 13 4 5.8
Functional — 52 assays, 11 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 49 1 6.8
assay format 3 10 6.4
ADME — 1 assays, 6 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 6 6.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine